|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Network, .
Comprehensive molecular portraits of human breast tumours. Nature.
490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
5
|
Lee RC and Ambros V: An extensive class of
small RNAs in Caenorhabditis elegans. Science. 294:862–864. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carleton M, Cleary MA and Linsley PS:
MicroRNAs and cell cycle regulation. Cell cycle. 6:2127–2132. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bentwich I, Avniel A, Karov Y, Aharonov R,
Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al:
Identification of hundreds of conserved and nonconserved human
microRNAs. Nat Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zamore PD and Haley B: Ribo-gnome: The big
world of small RNAs. Science. 309:1519–1524. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS,
Lee JH, Koo KH, Park JW and Kim KS: miR-372 regulates cell cycle
and apoptosis of ags human gastric cancer cell line through direct
regulation of LATS2. Mol Cells. 28:521–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu G, Liu H, He H, Wang Y, Lu X, Yu Y, Xia
S, Meng X and Liu Y: miR-372 down-regulates the oncogene ATAD2 to
influence hepatocellular carcinoma proliferation and metastasis.
BMC Cancer. 14:1072014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu J, Jin L, Jiang L, Gao L, Zhou J, Hu Y,
Li W, Zhi Q and Zhu X: Serum miR-372 is a diagnostic and prognostic
biomarker in patients with early colorectal cancer. Anticancer
Agents Med Chem. 16:424–431. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Voorhoeve PM, le Sage C, Schrier M, Gillis
AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A,
et al: A genetic screen implicates miRNA-372 and miRNA-373 as
oncogenes in testicular germ cell tumors. Cell. 124:1169–1181.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qi J, Yu JY, Shcherbata HR, Mathieu J,
Wang AJ, Seal S, Zhou W, Stadler BM, Bourgin D, Wang L, et al:
microRNAs regulate human embryonic stem cell division. Cell Cycle.
8:3729–3741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yeh LY, Liu CJ, Wong YK, Chang C, Lin SC
and Chang KW: miR-372 inhibits p62 in head and neck squamous cell
carcinoma in vitro and in vivo. Oncotarget. 6:6062–6075. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tian RQ, Wang XH, Hou LJ, Jia WH, Yang Q,
Li YX, Liu M, Li X and Tang H: MicroRNA-372 is down-regulated and
targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human
cervical cancer, which may contribute to tumorigenesis. J Biol
Chem. 286:25556–25563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gu H, Guo X, Zou L, Zhu H and Zhang J:
Upregulation of microRNA-372 associates with tumor progression and
prognosis in hepatocellular carcinoma. Mol Cell Biochem. 375:23–30.
2013.PubMed/NCBI
|
|
18
|
Yabuta N, Okada N, Ito A, Hosomi T,
Nishihara S, Sasayama Y, Fujimori A, Okuzaki D, Zhao H, Ikawa M, et
al: Lats2 is an essential mitotic regulator required for the
coordination of cell division. J Biol Chem. 282:19259–19271. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He K, Zheng X, Li M, Zhang L and Yu J:
mTOR inhibitors induce apoptosis in colon cancer cells via
CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation. Oncogene.
35:148–157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He K, Chen D, Ruan H, Li X, Tong J, Xu X,
Zhang L and Yu J: BRAFV600E-dependent Mcl-1 stabilization leads to
everolimus resistance in colon cancer cells. Oncotarget.
7:47699–47710. 2016.PubMed/NCBI
|
|
21
|
Liu H, Bockhorn J, Dalton R, et al: Roles
of miRNAs in breast cancer stem cells, drug sensitivity and
spontaneous metastases in orthotopic human-in-mouse models. J Clin
Oncol. 29:2011. View Article : Google Scholar
|
|
22
|
Mulrane L, McGee SF, Gallagher WM and
O'Connor DP: miRNA dysregulation in breast cancer. Cancer Res.
73:6554–6562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Serpico D, Molino L and Di Cosimo S:
microRNAs in breast cancer development and treatment. Cancer Treat
Rev. 40:595–604. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA 10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guttilla IK and White BA: Coordinate
regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast
cancer cells. J Biol Chem. 284:23204–23216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chiang CH, Hou MF and Hung WC:
Up-regulation of miR-182 by β-catenin in breast cancer increases
tumorigenicity and invasiveness by targeting the matrix
metalloproteinase inhibitor RECK. Biochim Biophys Acta.
1830:3067–3076. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu JJ, Guo H, Li H, Liu Y, Liu J, Chen L,
Zhang J and Zhang N: miR-145 regulates epithelial to mesenchymal
transition of breast cancer cells by targeting Oct4. PLoS One.
7:e459652012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Huang J, Yang N, Greshock J,
Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR,
et al: microRNAs exhibit high frequency genomic alterations in
human cancer. Proc Natl Acad Sci USA. 103:pp. 9136–9141. 2006;
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu BL, Sun KX, Zong ZH, Chen S and Zhao
Y: MicroRNA-372 inhibits endometrial carcinoma development by
targeting the expression of the Ras homolog gene family member C
(RhoC). Oncotarget. 7:6649–6664. 2016.PubMed/NCBI
|
|
30
|
Zhang M, Wang X, Li W and Cui Y: miR-107
and miR-25 simultaneously target LATS2 and regulate proliferation
and invasion of gastric adenocarcinoma (GAC) cells. Biochem Biophys
Res Commun. 460:806–812. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee KH, Goan YG, Hsiao M, Lee CH, Jian SH,
Lin JT, Chen YL and Lu PJ: MicroRNA-373 (miR-373)
post-transcriptionally regulates large tumor suppressor, homolog 2
(LATS2) and stimulates proliferation in human esophageal cancer.
Exp Cell Res. 315:2529–2538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu A, Li J, Wu K, Mo Y, Luo Y, Ye H, Mai
Z, Guo K, Wang Y, Li S, et al: LATS2 as a poor prognostic marker
regulates non-small cell lung cancer invasion by modulating MMPs
expression. Biomed Pharmacother. 82:290–297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takahashi Y, Miyoshi Y, Takahata C,
Irahara N, Taguchi T, Tamaki Y and Noguchi S: Down-regulation of
LATS1 and LATS2 mRNA expression by promoter hypermethylation and
its association with biologically aggressive phenotype in human
breast cancers. Clin Cancer Res. 11:1380–1385. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y, Pei J, Xia H, Ke H, Wang H and Tao
W: Lats2, a putative tumor suppressor, inhibits G1/S transition.
Oncogene. 22:4398–4405. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ke H, Pei J, Ni Z, Xia H, Qi H, Woods T,
Kelekar A and Tao W: Putative tumor suppressor Lats2 induces
apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell
Res. 298:329–338. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Britschgi A, Duss S, Kim S, Couto JP,
Brinkhaus H, Koren S, De Silva D, Mertz KD, Kaup D, Varga Z, et al:
The Hippo kinases LATS1 and 2 control human breast cell fate via
crosstalk with ERα. Nature. 541:541–545. 2017. View Article : Google Scholar : PubMed/NCBI
|
